Smoking reduces the efficacy of belimumab in mucocutaneous lupus

References

• Ghaussy NO, Sibbitt WL Jr., Qualls CR. Cigarette smoking, alcohol consumption, and the risk of systemic lupus erythematosus: a case-control study. J Rheumatol. 2001;28(11):2449–2453.
   PubMed Web of Science ®Google Scholar
• Costenbader KH, Kim DJ, Peerzada J, et al. Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum. 2004;50(3):849–857.
   PubMed Web of Science ®Google Scholar
• Freemer MM, King TE, Jr., Criswell LA. Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus. Ann Rheum Dis. 2006;65(5): 581–584.
   PubMed Web of Science ®Google Scholar
• Ekblom-Kullberg S, Kautiainen H, Alha P, et al. Smoking and the risk of systemic lupus erythematosus. Clin Rheumatol. 2013;32(8):1219–1222.
   PubMed Web of Science ®Google Scholar
• Jiang F, Li S, Jia C. Smoking and the risk of systemic lupus erythematosus: an updated systematic review and cumulative meta-analysis. Clin Rheumatol. 2015;34(11):1885–1892.
   PubMed Web of Science ®Google Scholar
• Versini M, Tiosano S, Comaneshter D, et al. Smoking and obesity in systemic lupus erythematosus: a cross-sectional study. Eur J Clin Invest. 2017;47(6):422–427.
   PubMed Web of Science ®Google Scholar
• Majka DS, Holers VM. Cigarette smoking and the risk of systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis. 2006;65(5):561–563.
   PubMed Web of Science ®Google Scholar
• Klareskog L, Padyukov L, Alfredsson L. Smoking as a trigger for inflammatory rheumatic diseases. Curr Opin Rheumatol. 2007;19(1):49–54.
   PubMed Web of Science ®Google Scholar
• Karlson EW, Lee IM, Cook NR, et al. A retrospective cohort study of cigarette smoking and risk of rheumatoid arthritis in female health professionals. Arthritis Rheum. 1999;42(5):910–917.
   PubMed Web of Science ®Google Scholar
• Uhlig T, Hagen KB, Kvien TK. Current tobacco smoking, formal education, and the risk of rheumatoid arthritis. J Rheumatol. 1999;26(1):47–54.
   PubMed Web of Science ®Google Scholar
• Stolt P, Bengtsson C, Nordmark B, et al. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis. 2003;62(9):835–841.
   PubMed Web of Science ®Google Scholar
• Saevarsdottir S, Wallin H, Seddighzadeh M, et al. Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. Ann Rheum Dis. 2011;70(3):469–475.
   PubMed Web of Science ®Google Scholar
• Saevarsdottir S, Wedren S, Seddighzadeh M, et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the epidemiological investigation of rheumatoid arthritis and the Swedish rheumatology register cohorts. Arthritis Rheum. 2011;63(1):26–36.
   PubMed Web of Science ®Google Scholar
• Ghaussy NO, Sibbitt W Jr., Bankhurst AD, et al. Cigarette smoking and disease activity in systemic lupus erythematosus. J Rheumatol. 2003;30(6):1215–1221.
   PubMed Web of Science ®Google Scholar
• Montes RA, Mocarzel LO, Lanzieri PG, et al. Smoking and its association with morbidity in systemic lupus erythematosus evaluated by the systemic lupus international collaborating clinics/American college of rheumatology damage index: preliminary data and systematic review. Arthritis Rheumatol. 2016;68(2):441–448.
   PubMed Web of Science ®Google Scholar
• Gustafsson JT, Gunnarsson I, Kallberg H, et al. Cigarette smoking, antiphospholipid antibodies and vascular events in systemic lupus erythematosus. Ann Rheum Dis. 2015;74(8):1537–1543.
   PubMed Web of Science ®Google Scholar
• Turchin I, Bernatsky S, Clarke AE, et al. Cigarette smoking and cutaneous damage in systemic lupus erythematosus. J Rheumatol. 2009;36(12):2691–2693.
   PubMed Web of Science ®Google Scholar
• Bourre-Tessier J, Peschken CA, Bernatsky S, et al. Association of smoking with cutaneous manifestations in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2013;65(8):1275–1280.
   PubMed Web of Science ®Google Scholar
• Chasset F, Frances C, Barete S, et al. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. J Am Acad Dermatol. 2015;72(4):634–639.
   PubMed Web of Science ®Google Scholar
• Dutz J, Werth VP. Cigarette smoking and response to antimalarials in cutaneous lupus erythematosus patients: evolution of a dogma. J Invest Dermatol. 2011;131(10):1968–1970.
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71(8):1343–1349.
   PubMed Web of Science ®Google Scholar
• Manzi S, Sanchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833–1838.
   PubMed Web of Science ®Google Scholar
• Collins CE, Dall’Era M, Kan H, et al. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA. Lupus Sci Med. 2016;3(1):e000118.
   PubMed Web of Science ®Google Scholar
• Scheinberg M, De Melo FFN, Bueno AN, et al. Belimumab for the treatment of corticosteroid-dependent systemic lupus erythematosus: from clinical trials to real-life experience after 1 year of use in 48 Brazilian patients. Clin Rheumatol. 2016;35(7):1719–1723.
   PubMed Web of Science ®Google Scholar
• Schwarting A, Schroeder JO, Alexander T, et al. First real-world insights into belimumab use and outcomes in routine clinical care of systemic lupus erythematosus in Germany: results from the OBSErve Germany Study. Rheumatol Ther. 2016. DOI:10.1007/s40744-016-0047-x.
   PubMed Web of Science ®Google Scholar
• Parodis I, Sjowall C, Jonsen A, et al. Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. Autoimmun Rev. 2017;16(4):343–351.
   PubMed Web of Science ®Google Scholar
• Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271–1277.
   PubMed Web of Science ®Google Scholar
• Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–2686.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288–291.
   PubMed Web of Science ®Google Scholar
• Albrecht J, Taylor L, Berlin JA, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005;125(5):889–894.
   PubMed Web of Science ®Google Scholar
• Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39(3):363–369.
   PubMed Web of Science ®Google Scholar
• Fuchs HA, Brooks RH, Callahan LF, et al. A simplified twenty-eight-joint quantitative articular index in rheumatoid arthritis. Arthritis Rheum. 1989;32(5):531–537.
   PubMed Web of Science ®Google Scholar
• Choi CB, Liang MH, Bae SC. Progress in defining clinically meaningful changes for clinical trials in nonrenal manifestations of SLE disease activity. Arthritis Res Ther. 2016;18:1.
   PubMed Web of Science ®Google Scholar
• Klein R, Moghadam-Kia S, LoMonico J, et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol. 2011;147(2):203–208.
   PubMedGoogle Scholar
• Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(11):1909–1916.
   PubMed Web of Science ®Google Scholar
• Bruce IN, Urowitz M, Van Vollenhoven R, et al. Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. Lupus. 2016;25(7):699–709.
   PubMed Web of Science ®Google Scholar
• Iaccarino L, Bettio S, Reggia R, et al. Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2017;69(1):115–123.
   PubMed Web of Science ®Google Scholar
• Hedstrom AK, Alfredsson L, Lundkvist, et al. Smokers run increased risk of developing anti-natalizumab antibodies. Mult Scler. 2014;20(8):1081–1085.
   PubMed Web of Science ®Google Scholar
• Hedstrom AK, Ryner M, Fink K, et al. Smoking and risk of treatment-induced neutralizing antibodies to interferon beta-1a. Mult Scler. 2014;20(4):445–450.
   PubMed Web of Science ®Google Scholar
• Khan A, Scott DL, Batley M. Smoking, rheumatoid factor status and responses to rituximab. Ann Rheum Dis. 2012;71(9):1587–1588.
   PubMed Web of Science ®Google Scholar
• Kirkham PA, Spooner G, Rahman I, et al. Macrophage phagocytosis of apoptotic neutrophils is compromised by matrix proteins modified by cigarette smoke and lipid peroxidation products. Biochem Biophys Res Commun. 2004;318(1):32–37.
   PubMed Web of Science ®Google Scholar
• Hung RJ, Boffetta P, Brennan P, et al. Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk. Carcinogenesis. 2004;25(6):973–978.
   PubMed Web of Science ®Google Scholar
• Wu X, Zhao H, Suk R, et al. Genetic susceptibility to tobacco-related cancer. Oncogene. 2004;23(38):6500–6523.
   PubMed Web of Science ®Google Scholar
• Vashisht P, Borghoff K, O’Dell JR, et al. Belimumab for the treatment of recalcitrant cutaneous lupus. Lupus. 2017;26(8):857–864.
   PubMed Web of Science ®Google Scholar